% | $
Quotes you view appear here for quick access.

Canaccord Genuity Group Inc. Message Board

mirror_world_man 8 posts  |  Last Activity: Mar 25, 2015 3:39 PM Member since: Mar 23, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    FDA agrees on SVC primary endpoint

    by aecooter33 Mar 25, 2015 12:14 PM
    mirror_world_man mirror_world_man Mar 25, 2015 3:39 PM Flag

    One important lesson from the B-ALS is to keep energy levels up, the trial population remains well fed during the Phase 3. No empty calories...

    Sentiment: Strong Buy

  • Reply to

    The news release

    by warrenw6630 Mar 25, 2015 10:02 AM
    mirror_world_man mirror_world_man Mar 25, 2015 1:31 PM Flag

    The knee jerk is not unusual in heavily shorted BT's of which CYTK is not, so it is a bit odd. I guessed the move to PIII was giving some BB's the tizzies of an offering to pay for the trials, or some people want in at a lower price. The results look ok after only a single dose. IMHO the bottom line is that those that dumped did so on automatic pilot, or have a longer range plan. I nibbled a bit on the way down, there is no harm as far as I can see.

    Sentiment: Strong Buy

  • mirror_world_man by mirror_world_man Mar 21, 2015 5:22 PM Flag

    Stocks that warrant a look in the health care sector include Cytokinetics, Inc. CYTK, Acorda Therapeutics, Inc. ACOR and Affymetrix Inc. AFFX. All of these carry a Zacks Rank #1 (Strong Buy). 2013 they said the same thing and CYTK popped to almost double a little later.

    Sentiment: Strong Buy

  • Reply to

    If the clsp short theory is correct,..

    by itsahorserace Jan 14, 2015 8:51 PM
    mirror_world_man mirror_world_man Jan 14, 2015 11:13 PM Flag

    purchase price is not necessarily related to price of P, but at the SP at the time of company purchase. If SP remains low, the buyout may be at a cheaper price than we immagine

  • Reply to

    latest 8k filing out

    by cln6631 Jan 9, 2015 5:49 PM
    mirror_world_man mirror_world_man Jan 10, 2015 12:09 AM Flag

    Are intangibles included in company's asset to achieve 1B for bonus purposes, or MC alone?

    Sentiment: Strong Buy

  • mirror_world_man mirror_world_man Jan 8, 2015 8:34 PM Flag

    IMHO a buyout is likely and will occur post FDA approval. SGYP has not got a marketing and sales core competency to move forward on commercialization. Likely BP suitors will look to add another drug to their current a GI agent(s) on their in-line Sales portfolio. It us fun to speculate and lots of action prior to that, I wish I waited to buy more at these prices. GLTA

    Sentiment: Strong Buy

  • mirror_world_man mirror_world_man Jan 7, 2015 4:35 PM Flag

    Seen this before, particularily in BT's. I agree with those that think it is a transfer of inexpensive ownership, with help of the lawyers and pulp media help to create FUD. Short Interest has not grown recently, suggesting perhaps they are not loading up. WRT this news, hands may be slapped, issues will be cleared, may be a medium fine or two for maybe going against ethical marketing practices. Be thankfull that all medications do not create any harm and it is not a patient or trial issue. No drugs will be pulled from the market, repeated infringments will create loftier fines in the future. So the appears of cleaner than clean will be the new norm. I just bought back in again. GLTA

    Sentiment: Strong Buy

  • mirror_world_man by mirror_world_man Dec 31, 2014 10:59 PM Flag

    Shares of Cytokinetics, Inc. (NASDAQ: CYTK) surged 16 percent Wednesday following Roth Capital raising its price target on the company from $13 to $18.

    The analyst note cited four facets for its strengthened investment case:

    1) "CYTK has shown its prowess in attracting significant partnerships in the form of both Amgen and Astellas,"

    2) "each of these partners have approximately the same equity stake in CYTK as well,"

    3) "a regulatory path forward for tirasemtiv for ALS is expected in the near term and, importantly,"

    4) "the company has a strong financial footing with 2-3 years of cash on hand with the recently expanded Astellas collaboration (~$150 million pro forma cash)."

    Analyst Joseph Pantginis concluded, “While the final trial design for a pivotal study has not yet been agreed upon with the FDA and EMEA, the trial design will likely contain and adaptive design as well as important interim analyses. This should allow CYTK to "titrate" their spending on the ALS study on an "as needed basis".”

    Cytokinetics recently traded at $8.03, up 16.4 percent.

    Latest Ratings for CYTK
    Date Firm Action From To
    Nov 2014 MLV & Co. Upgrades Hold Buy
    May 2014 Leerink Swann Maintains Outperform
    Apr 2014 Piper Jaffray Downgrades Overweight Neutral

    Sentiment: Strong Buy

6.52+0.05(+0.77%)Mar 31 4:00 PMEDT